SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) — Nkarta, Inc. NKTXa biopharmaceutical company developing engineered natural killer (NK) cell therapies for the treatment of cancer, today announced it will be attending two upcoming investor conferences:
22nd Annual Needham Virtual Healthcare Conference
April 17, 2023
3:00 p.m. ET – Fireside chat
Canaccord Genuity Horizons in Virtual Oncology Conference
April 20, 2023
3:00 p.m. ET – Panel discussion
A simultaneous webcast of each event will be available in the Investors section of Nkarta’s website. www.nkartatx.comand a replay will be archived on the site for approximately 90 days.
About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, commercial natural killer (NK) cell therapies for cancer patients. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genomic engineering capabilities, Nkarta is building a pipeline of future cell therapies designed for deep anti-tumor activity and broad access in the outpatient setting treatment environment are provided. For more information, visit the company’s website at www.nkartatx.com.
Nkarta Media/Investor Contact:
Gregory Mann
Nkarta, Inc.
gmann@nkartatx.com
[ad_2]
Source story
